Clinical Trial Update: Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. [Phase 2]

View source ↗

Summary

Phase 2 trial of donor lymphocytes labeled with in-vitro bispecific antibodies for metastatic solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Donor lymphocytes labeled with in-vitro bispecific antibodies

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Metastatic Solid Tumors | Phase 2 | Status: WITHDRAWN